VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
0.3605
+0.0002 (0.06%)
Nov 20, 2025, 8:16 AM EST - Market open
VYNE Therapeutics Revenue
VYNE Therapeutics had revenue of $169.00K in the quarter ending September 30, 2025, with 39.67% growth. This brings the company's revenue in the last twelve months to $524.00K, up 6.29% year-over-year. In the year 2024, VYNE Therapeutics had annual revenue of $501.00K with 18.16% growth.
Revenue (ttm)
$524.00K
Revenue Growth
+6.29%
P/S Ratio
29.36
Revenue / Employee
$40,308
Employees
13
Market Cap
12.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 501.00K | 77.00K | 18.16% |
| Dec 31, 2023 | 424.00K | -53.00K | -11.11% |
| Dec 31, 2022 | 477.00K | -454.00K | -48.76% |
| Dec 31, 2021 | 931.00K | -20.06M | -95.57% |
| Dec 31, 2020 | 20.99M | 20.55M | 4,638.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VYNE News
- 14 days ago - VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo - GlobeNewsWire
- 5 months ago - VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - Benzinga
- 7 months ago - VYNE Therapeutics Provides Update on VYN202 Program - GlobeNewsWire
- 8 months ago - VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire